Aplagon Appoints Carl Lindgren as Board Chair to Guide Later Stage Clinical and Corporate Development

Source Summary

Veteran life sciences executive brings over 30 years of strategic and commercial leadership as Aplagon advances through Phase 2 development in multiple thrombosis-inflammatory diseases Veteran life sciences executive brings over 30 years of strategic and commercial leadership as Aplagon advances through Phase 2 development in multiple thrombosis-inflammatory diseases